New anticoagulant strategies in ST elevation myocardial infarction: Trials and clinical implications

Conor J McCann
Ian BA Menown
Craigavon Cardiac Centre, Craigavon Area Hospital, Craigavon, Northern Ireland, UK

Abstract: New data have re-established the importance of anticoagulation of patients with ST segment elevation myocardial infarction ( STEMI), both as an adjuvant to reperfusion therapy or in patients ineligible for reperfusion. Recent randomized trials have found newer agents to be superior to conventional unfractionated heparin. This article summarizes current understanding of the underlying pathophysiology of STEMI and provides a comprehensive review of emerging trial data for low molecular weight heparins, anti-factor Xa agents and direct thrombin inhibitors in this setting.

Keywords: myocardial infarction, treatment, anticoagulants

Introduction
The contemporary approach to a patient with ischemic-type chest pain is to categorize them as experiencing an acute coronary syndrome (ACS) with or without ST segment elevation. The assessment of the initial 12-lead electrocardiogram (ECG) is therefore of critical importance as the management strategy is different for each group (Antman et al 2004; Braunwald et al 2002). Prompt identification of patients with acute ST segment elevation myocardial infarction ( STEMI) is vital if patients are to benefit from contemporary management strategies. Over the last 3 decades, major advances in our understanding of the pathophysiological processes responsible for STEMI and its sequelae have allowed development of pharmacological therapies to target these different processes. Numerous large well designed randomized controlled trials have guided determination of ever superior management strategies and their increasing utilization has been associated with a corresponding steady decline in death from acute myocardial infarction (MI) (Goldberg et al 2004).

Pathophysiology of STEMI
Complex inflammatory mechanisms are now known to participate in all stages of coronary artery disease, from the initial development of the fatty streak, through progression to advanced atherosclerotic lesions causing angina pectoris, to plaque disruption and thrombus formation. Plaques vulnerable to disruption and rupture are frequently non-obstructive but have a large lipid-rich core and a high macrophage content leading to thinning of the fibrous cap (Moreno et al 1994; Davies 2000; Shah 2003). Plaque rupture, which typically occurs at the edge or shoulder region, exposes the lipid core, leading to platelet adhesion and aggregation, activation of the coagulation cascade, and formation of a platelet rich thrombus. A key step in this process is activation of prothrombin to thrombin (factor IIa) which promotes the formation of fibrin, the protein which acts as a scaffold in stable thrombus. The fate of the thrombus then ranges from simple incorporation into the plaque, through subtotal artery occlusion,
to fully occlusive thrombus formation (Corti et al 2003), the latter typically presenting clinically as STEMI (DeWood et al 1980).

Reperfusion strategies for STEMI
Where possible, the immediate treatment goal in STEMI is to disperse the thrombus thereby restoring coronary blood flow to the culprit artery (Antman et al 2004) in order to limit infarct size, to preserve left ventricular function, and ultimately, to reduce mortality.

Two decades on from the landmark GISSI trial with streptokinase, fibrinolytic therapy remains the most widely used reperfusion strategy (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) 1986). Second and third generation fibrinolytic agents interact directly with clot-bound plasminogen improving fibrin selectivity and achieve higher rates of early patency although this has translated at most into only a small further reduction in mortality. More important than the fibrinolytic agent used is the time delay from symptom onset to drug administration (Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group 1994; Boersma et al 1996) and hence the value of third generation bolus agents which help facilitate pre-hospital use.

Catheter based reperfusion with primary percutaneous coronary intervention (PCI) where available within a reasonable timeframe, may lead to even better reduction in cardiovascular events, except in patients who present very rapidly after symptom onset when both strategies appear to be equivalent (Keeley et al 2003; Steg et al 2003). Primary PCI is associated with a reduced risk of bleeding complications, in particular intracranial hemorrhage (Keeley et al 2003) which typically occurs in approximately 1% of patients treated with a fibrinolytic based regimen. Trials have shown that the adjuvant anticoagulant dose may play a significant role in the risk of intracranial hemorrhage (Giugliano et al 2001).

Adjuvant antiplatelet therapy
The importance of adjuvant aspirin was established in ISIS-2 (Second International Study of Infarct Survival) Collaborative Group 1988) and the value of concurrent clopidogrel in the more recent CLARITY and COMMIT trials (Chen et al 2005; Sabatine et al 2005). It is likely that their primary benefit is to reduce reocclusion following successful reperfusion (Scirica et al 2006). Initial trials of glycoprotein IIb/IIIa receptor antagonists in combination with reduced dose fibrinolytic appeared promising, improving early patency and ST resolution (Antman et al 1999). However the large GUSTO V trial found only a small efficacy advantage in selected subgroups which was offset by a significant increase in bleeding risk (Gurm et al 2004).

Adjuvant anticoagulant therapy
While adjuvant anticoagulant therapy may give a small improvement in patency (Ross et al 2001), like antiplatelet therapy, its main role is in helping to maintain patency after successful reperfusion. Additional potential benefits include prevention of deep venous thrombosis, pulmonary embolism and left ventricular thrombus. Current therapy choices include conventional unfractionated heparin (UFH) and newer agents, in particular low molecular weight heparin (LMWH), factor Xa inhibitors and direct thrombin inhibitors. The mechanism of action of these agents is illustrated in Figure 1.

The guidelines mandate the concomitant use of anti-coagulant treatment with either pharmacological or mechanical reperfusion (Antman et al 2004). An area of controversy has existed regarding the need of otherwise for anticoagulation with streptokinase as the latter induces prolonged fibrin depletion. Two meta-analyses, both published in 1996, failed to show evidence of clear benefit with adjuvant UFH (Collins et al 1996; Mahaffey et al 1996). However, more recent placebo controlled data have demonstrated benefit for use of concomitant LMWH (Simoons et al 2002; Yusuf et al 2005) and factor Xa inhibition (Yusuf et al 2006) with streptokinase. Of note there is a paucity of placebo-controlled evidence for use of adjuvant anticoagulation with the fibrin-specific agents, or indeed primary PCI, mainly because of a presumption that anticoagulation use in these settings is clearly indicated.

Unfractionated heparin
Heparin is a heterogeneous mucopolysaccharide which interacts with antithrombin-III greatly increasing its inhibitory effects on thrombin (Hirsh and Fuster 1994). The heparin-antithrombin-III complex also has inhibitory effects on factor Xa and other clotting factors. Use of concurrent intravenous heparin has been shown to decrease early thrombin activity, improve culprit artery patency and reduce reocclusion, although the value of delayed subcutaneous (SC) heparin following fibrinolytic therapy is less clear (The GUSTO Angiographic Investigators 1993; Mahaffey et al 1996; Granger et al 1998). A recent meta-analysis failed to show a clear benefit for UFH compared to placebo (Eikelboom et al 2005). A major drawback with UFH is the significant variability in therapeutic response which occurs because of its heterogeneous composition and necessitates close
monitoring of the activated partial thromboplastin time (aPTT). The typical regimen for use in STEMI is an initial bolus of 60 U/kg (max 4000 U) and continued as an infusion of 12 U/kg/hr (max 1000 U/hr) for 48 hours adjusted to achieve an aPTT of 50–70 seconds. It is notoriously difficult to achieve and maintain the aPTT within this target range, and under-treatment is a significant problem. In the TIMI 9B trial only approximately one third of patients had an aPTT within the target range at any given time, with between 25%–52% having sub-therapeutic levels (Antman et al 1996). Ensuring that the aPTT does not rise above 70 seconds is of vital importance because, once exceeded, the absolute risk of intracranial hemorrhage rises in direct proportion to the aPTT (Granger et al 1996). UFH can also give rise to an immunologically mediated thrombocytopenia known as heparin induced thrombocytopenia (HIT) which is rare but potentially life threatening. These drawbacks, together with the requirement for continuous intravenous (IV) administration, make UFH a less than ideal anticoagulant agent.

**Low molecular weight heparin**

LMWHs are approximately one third of the molecular weight of UFH, conferring greater bioavailability following subcutaneous administration (Antman 2001). Weight adjusted SC bolus dosing leads to stable and reliable anticoagulation without the need for monitoring, meaning they are much

---

**Abbreviations:** UFH, unfractionated heparin; LMWH, low molecular weight heparin; DTI, direct thrombin inhibitors.
more convenient to administer in clinical practice. As well as improving bioavailability, once binding to antithrombin-III occurs, greater relative specificity for factor Xa is provided when compared to UFH, producing enhanced blockade of the coagulation cascade upstream of thrombin generation. The ratio of inhibition of factor Xa:IIa varies between agents (for enoxaparin the ratio is 3:1) (Armstrong 1997). HIT is less common with LMWH compared to UFH (Warkentin et al 1995), but it is important to remember that, because LMWHs are made by depolymerisation of UFH, they can still give rise to this condition.

Placebo controlled studies with LMWH have confirmed the importance of an adjuvant anticoagulant strategy. The AMI-SK study of 496 streptokinase treated MI patients showed that adjuvant enoxaparin compared with placebo improved early patency by 22%, improved early ST-segment resolution and was associated with a 36% reduction in the composite of death, reinfarction and recurrent angina (Simoons et al 2002). The CREATE trial compared the LMWH reviparin with placebo in 15570 patients with STEMI (Yusuf et al 2005), of whom 73% received fibrinolytic therapy and 6.1% underwent primary PCI, the remainder being treated conservatively. Reviparin significantly reduced the composite endpoint of death, reinfarction and stroke although those receiving fibrinolytic therapy had an increased the risk of major bleeding including intracranial hemorrhage (0.4% vs 0.1% for reviparin and placebo groups respectively).

Enoxaparin has been extensively compared to UFH following fibrinolytic therapy for acute MI (see Table 1). Follow- ing early studies (Baird et al and HART II), the ASSENT-3 trial randomized over 6000 patients receiving tenecteplase to full-dose tenecteplase and enoxaparin, half-dose tenecteplase with weight-adjusted low-dose UFH and a 12-hour abciximab infusion, or full-dose tenecteplase with 48 hours UFH (Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators 2001). Administration of enoxaparin with full dose tenecteplase led to significant reductions in 30-day mortality, in-hospital reinfarction and in-hospital recurrent ischemia compared with UFH, with no significant increase in overall bleeding.

However, the ASSENT-3 PLUS study of over 1600 pre- hospital patients (Wallentin et al 2003) showed an excess of intracranial hemorrhage with enoxaparin in patients ≥75 years, suggesting that a dose reduction was needed in this age group. The pivotal 20475 patient ExTRACT-TIMI 25 study (Antman et al 2006) thus compared UFH (standard bolus and 48 hour infusion) with a modified enoxaparin regimen – standard 30 mg IV bolus then 1 mg/kg bd until hospital discharge, but reduced dose in patients ≥75 yrs (no initial IV bolus, SC dose reduced to 0.75 mg/kg) and a reduced frequency (once a day) in patients with impaired renal function. Median treatment duration with UFH was 2.0 days (interquartile range 2.0–2.2) and with enoxaparin was 7.0 days (interquartile range 4.5–7.5). Enoxaparin was associated with a 17% reduction in death or MI (9.9% vs 12%; p < 0.001), excess major bleeding (2.1% vs 1.4%) but no excess of intra-cranial hemorrhage (0.8% vs 0.7%; p = 0.14) and overall net clinical benefit. Although it may be argued that ExTRACT was a comparison of treatment durations rather than drugs, even at 48 hours, the composite of death, MI and urgent revascularization was significantly reduced with enoxaparin treatment (6.1% vs 5.3%; p = 0.02). Based on ExTRACT trial data, the Food and Drug Administration have formally approved enoxaparin for use in ST elevation MI.

A planned substudy of the ExTRACT trial (ExTRACT-PCI) evaluated whether enoxaparin was superior to UFH in those STEMI patients (almost a quarter of the total study cohort) who received thrombolytic therapy and subsequently underwent PCI within 30 days (Gibson et al 2007). By 30 days, patients randomised to enoxaparin showed a 23% relative reduction in death or MI compared to UFH (10.7% vs. 13.8%; p = 0.001) without a significant difference in the risk of major bleeding. Almost one half of the patients in this substudy underwent PCI while still receiving blinded study drug. Again, for this cohort, a reduction in 30 day death or MI risk was seen in the enoxaparin group compared to the UFH group (13.0% vs 16.7%; p = 0.013) without an increased risk of major bleeding.

**Pentasaccharides**

Pentasaccharides are manufactured to have a chemical structure similar to the antithrombin-III binding domain (active site) of heparin. Binding of pentasaccharide to antithrombin-III induces conformational changes leading to selective and potent inhibition of factor Xa resulting in greatly reduced thrombin generation (Coussement et al 2001). Unlike UFH and LMWH there is no inhibitory effect on thrombin molecule itself. Pentasaccharides, such as fondaparinux, can therefore be considered as synthetic, highly selective, indirect inhibitors of factor Xa. Potential advantages of fondaparinux include 100% bioavailability after subcutaneous injection, a long half-life of 15–18 hours allowing for once daily administration, predictable anticoagulant effect with no requirement for monitoring, and no cross-reactivity with antibodies associated with HIT (Walenga et al 1997; Efird and Kockler 2006). Also, selective and potent targeting of an upstream step in the coagulation
Table 1 Important randomized controlled trials comparing LMWH with UFH in patients treated with fibrinolytic therapy for STEMI

| Trial          | Patients | LMWH regimen                      | UFH regimen                              | Outcomes                                                                 |
|---------------|----------|-----------------------------------|------------------------------------------|--------------------------------------------------------------------------|
| Baird et al†  | 300      | Enoxaparin 40 mg IV bolus + 40 mg SC hourly for 4 days | IV bolus, then infusion to maintain aPTT 2–2.5 × normal for 36 hours | • Significant reduction in death, non-fatal reinfarction or readmission with unstable angina at 90 days in favor of enoxaparin.  
• No significant difference in major hemorrhage.  
• Enoxaparin non-inferior to UFH.  
• No significant difference in adverse events. |
| HART II†      | 400      | Enoxaparin 30 mg IV bolus + 1 mg/kg SC 12 hourly for ≥72 hours | IV bolus, then infusion to maintain aPTT 2–2.5 × normal for ≥77 hours | • No significant difference in TIMI 3 flow at 1 hour.  
• Significant reduction in death/re-infarction at 30 days for enoxaparin compared with UFH.  
• No significant difference in major bleeding. |
| ENTIRE-TIMI 23† | 483     | Enoxaparin 30 mg IV bolus + 1 mg/kg SC 12 hourly for 8 days or discharge | IV bolus, then infusion to maintain aPTT 1.5–2.5 × normal for ≥36 hours | • Significant reductions in 30-day mortality, in-hospital reinfarction and in-hospital recurrent ischemia for enoxaparin compared with UFH.  
• No significant increase in overall bleeding. |
| ASSENT-3†     | 6095     | Enoxaparin 30 mg IV bolus + 1 mg/kg SC 12 hourly for 7 days or discharge (2040 patients) | IV bolus, then infusion to maintain aPTT 50–70s for ≥48 hours (2038 patients) | • Reduction in early ischemic events with enoxaparin.  
• Excess intracranial hemorrhage in patients >75 years.  
• Significant reduction in death or re-infarction.  
• Significant increase in major bleeding.  
• No significant difference in intracranial hemorrhage. |
| ASSENT-3 PLUS† | 1639 (pre-hospital) | Enoxaparin 30 mg IV bolus + 1 mg/kg SC 12 hourly for 7 days or discharge | IV bolus, then infusion to maintain aPTT 50–70s for ≥48 hours | • Reduction in early ischemic events with enoxaparin.  
• Excess intracranial hemorrhage in patients >75 years.  
• Significant reduction in death or re-infarction.  
• Significant increase in major bleeding.  
• No significant difference in intracranial hemorrhage. |
| ExTRACT†     | 20475    | Enoxaparin 30 mg IV bolus + 1 mg/kg SC 12 hourly for 8 days or discharge | IV bolus, then infusion to maintain aPTT 1.5–2 × normal for ≥48 hours | • Reduction in early ischemic events with enoxaparin.  
• Excess intracranial hemorrhage in patients >75 years.  
• Significant reduction in death or re-infarction.  
• Significant increase in major bleeding.  
• No significant difference in intracranial hemorrhage. |

†Baird et al 2002.  
‡Ross et al 2001.  
§Antman et al 2002.  
¶Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators 2001.  
⁎Third arm in this trial was half-dose tenecteplase with weight-adjusted low-dose UFH and a 12-hour abciximab infusion.  
†Wallentin et al 2003.  
‡Antman et al 2006.  
Regimen included a reduced dose in patients ≥75 years (no initial IV bolus, SC dose reduced to 0.75 mg/kg) and a reduced frequency (once a day) in patients with impaired renal function.  
Abbreviations: LMWH, low molecular weight heparin; UFH, unfractionated heparin; IV, intravenous; SC, subcutaneous.

cascade theoretically achieves superior anticoagulation as inhibition of one molecule of factor Xa reduces the downstream production of many molecules of thrombin (Antman 2001). Table 2 summarizes the significant results from the two clinical end-point trials which investigate fondaparinux use in STEMI patients.

The PENTALYSE study compared 5–7 days fondaparinux (4 mg, 8 mg, or 12 mg, initial dose IV then SC daily) with 48–72 hours UFH in 326 STEMI patients being treated with aspirin and alteplase (Coussen et al 2001). There was no difference in early artery patency determined by 90 minute coronary angiography. Patients who did not have coronary intervention during the treatment period, showed a trend to less reocclusion with fondaparinux (repeat angiography day 5–7). PENTALYSE reported a trend to increased instrumental bleeding but no overall increase in hemorrhage.  

The large multi-centre OASIS 6 trial (Yusuf et al 2006) is the first large scale trial to report on the efficacy and safety of fondaparinux in the setting of STEMI and therefore provides an extremely important extension of available evidence. It enrolled 12092 STEMI patients from 41 countries and randomized them in a complex design to fondaparinux (2.5 mg once daily for up to 8 days) or usual care which was defined as either placebo alone where UFH was not indicated (stratum 1, n = 5658), or UFH for up to 48 hours followed by placebo for up to 8 days in patients with an indication for UFH (stratum 2, n = 6434). The initial dose of fondaparinux was SC in stratum 1 and IV in stratum 2. The decision as to whether UFH was indicated was not predefined but based on the investigator’s judgment. As with ExTRACT, it is important to note that stratum 2 was not only comparing 2 anticoagulants, but also 2 anticoagulation strategies. UFH was given for up to
48 hours only, while fondaparinux was given for up to 8 days. Fibrinolytic therapy was used in 45% of the patients (78.0% in stratum 1 and 15.9% in stratum 2), with streptokinase being the most commonly used (approximately 73%). Primary PCI was undertaken in 28.9% (0.2% in stratum 1 and 53.2% in stratum 2). Almost a quarter of patients (23.7%) did not receive any reperfusion therapy. The primary endpoint (death/re-MI) in stratum 1 patients was significantly reduced by fondaparinux compared with placebo (11.2 vs 14.0; HR 0.79 [95% CI 0.68–0.92]). This adds to existing evidence (from AMI-SK and CREATE trials) confirming adjuvant antithrombotic therapy is indicated along with fibrinolytic therapy, including streptokinase. In stratum 2 patients, there was no significant reduction in the primary endpoint for fondaparinux compared with UFH (8.3 vs 8.7; HR 0.96 [95% CI 0.81–1.13]). Also of note, in patients undergoing primary PCI there was an increase in complications with fondaparinux compared with UFH including guide catheter thrombosis, abrupt coronary artery closure, new angiographic thrombus, or no reflow. An interim protocol modification advising additional UFH in fondaparinux patients undergoing acute PCI was thus required.

Several conclusions can be drawn from the OASIS-6 trial. There is clear benefit for fondaparinux in STEMI patients without an indication for UFH, where it is as safe as no anticoagulation. In conservatively managed STEMI patients with an indication for UFH who receive fibrinolytic therapy, fondaparinux is at least as effective and as safe as UFH. However, the use of fondaparinux as the sole anticoagulant for STEMI patients treated with primary PCI is associated with an increased risk of thrombotic complications, and thus pre-treatment with UFH before PCI is required.

### Direct thrombin inhibitors

Unlike UFH, direct thrombin (factor IIa) inhibitors inactivate clot bound thrombin and prevent thrombin induced platelet aggregation. In the large GUSTO IIb trial (Metz et al 1998) 2274 patients treated with fibrinolytic therapy for STEMI were randomly assigned to the direct thrombin inhibitor hirudin or UFH. In patients receiving streptokinase, hirudin compared with UFH was associated with a reduction in 30 day death/re-MI (8.6% vs 14.4%; p = 0.004) although no difference was seen in patients treated with tissue-type plasminogen activator (see Table 3). In the HIT 4 study (Neuhaus et al 1999), 1208 patients with STEMI were

---

**Table 2 Clinical endpoint trials for the use of fondaparinux in STEMI patients**

| Trial | Patients regimen | Fondaparinux regimen | UFH regimen | Outcomes |
|-------|------------------|-----------------------|-------------|----------|
| PENTALYSE<sup>a</sup> | 326 patients receiving fibrinolytic therapy | 4 mg, 8 mg, or 12 mg, initial dose IV then SC once daily for 5–7 days | IV bolus, then infusion to maintain aPTT 50–75s for 48–72 hours | • Fondaparinux as safe and effective as UFH in restoring coronary flow and preventing reocclusion. |
| OASIS-6<sup>b</sup> | Stratum 1: 5658 patients | 2.5 mg SC once daily for up to 8 days | Placebo | • Fondaparinux associated with a significant reduction in death or reinfarction compared with placebo. • Fondaparinux associated with fewer major bleeds than placebo (non-significant). • No significant difference in death or reinfarction between fondaparinux and UFH arms. • No significant difference in bleeding. |
| Stratum 2: 6434 patients | 2.5 mg IV bolus then 2.5 mg SC once daily for up to 8 days | IV bolus, then infusion to maintain aPTT 1.5–2× normal for up to 48 hours | |

<sup>a</sup>Coussement et al 2001.  
<sup>b</sup>Yusuf et al 2006.  

**Abbreviations:** UFH, unfractionated heparin; IV, intravenous; SC, subcutaneous.

The reason for a reduction in major bleeding is not well understood – some suggesting it may be a consequence of better clinical outcome and/or reduced need for urgent revascularization. In stratum 2, the rates of severe and major bleeds were similar in the 2 groups.

---

**Table 3**

| DI | 2.5 mg s.c. once daily for 4 days | 4 mg/kg bolus, then 4 mg/kg/h as IV infusion for 4 days | aPTT 60–100 s | • Fondaparinux associated with a significant reduction in death or reinfarction compared with placebo. |
| OASIS-6<sup>b</sup> | Stratum 1: 5658 patients | Placebo | • Fondaparinux associated with fewer major bleeds than placebo (non-significant). • No significant difference in death or reinfarction between fondaparinux and UFH arms. • No significant difference in bleeding. |
| Stratum 2: 6434 patients | 2.5 mg IV bolus then 2.5 mg SC once daily for up to 8 days | IV bolus, then infusion to maintain aPTT 1.5–2× normal for up to 48 hours | |

<sup>a</sup>Coussement et al 2001.  
<sup>b</sup>Yusuf et al 2006.  

**Abbreviations:** UFH, unfractionated heparin; IV, intravenous; SC, subcutaneous.
New anticoagulant strategies in STEMI

A trend to earlier ST resolution was seen, but no difference in reinfarction, mortality or bleeding rates.

A similar direct thrombin inhibitor, bivalirudin, showed improved early patency compared with UFH as an adjunct to streptokinase in the HERO study (White et al 1997). In the large 17073 patient HERO-2 study, bivalirudin as an adjunct to streptokinase did not reduce mortality at 30 days compared with UFH, but did reduce the rate of re-infarction within 4 days by 30% (White et al 2001). It is noteworthy that, unlike ExTRACT and OASIS-6, this trial compared identical treatment durations of the anticoagulants under investigation (48 hour infusion).

The advantage of bivalirudin over UFH in terms of reduced reinfarction came at the cost of a relatively small increase in moderate bleeding (1.4% vs 1.1%; p = 0.05). There was no significant difference in the risk of severe bleeding. This finding of increased moderate bleeding is not consistent with previous trials (Kong et al 1999).

Again, more recently, bivalirudin has been associated with reduced bleeding compared with UFH plus antiplatelet glycoprotein IIb/IIIa inhibitors during early PCI for non-ST elevation acute coronary syndromes (Stone et al 2006). It is currently being evaluated in the HORIZONS primary PCI STEMI trial, which is comparing bivalirudin to heparin plus glycoprotein IIb/IIIa inhibitor.

Summary and conclusions
The role of UFH in STEMI, particularly as an adjunct to fibrinolytic therapy, is being strongly challenged by the wealth of data surrounding newer anticoagulants including LMWH, factor Xa inhibitors and direct thrombin inhibitors. The evidence base is strongest for the LMWH enoxaparin where meta-analyses of multiple trials and the large ExTRACT trial have confirmed that enoxaparin (dose-adjusted for weight, renal function and age ≥ 75) compared with UFH, results in significant net clinical benefit. The recently published substudy of ExTRACT demonstrated superiority of enoxaparin over UFH in the patients who underwent PCI within 30 days of fibrinolytic therapy for STEMI, without a significant difference in bleeding. The results of this study also suggest that for patients commenced on adjuvant enoxaparin after fibrinolytic therapy there is no need to switch to UFH if they proceed to PCI during the period of anticoagulation. Thus while based on current evidence, enoxaparin may be considered the anticoagulant of choice in STEMI, the factor Xa inhibitor fondaparinux suggests the intriguing possibility of further reduction in bleeding risk without loss of efficacy. OASIS-6 has provided important data on ‘real-world’ use of fondaparinux, but because of the heterogeneous trial population and dependence on local investigator discretion to decide on the appropriateness of anticoagulant therapy, drawing firm conclusions for contemporary practice is difficult. Addi-
tionally, given the increasing provision of early PCI after successful fibrinolysis or rescue PCI after failed fibrinolytic limitation, the excess of guide catheter thrombosis is an apparent limitation. While the direct thrombin inhibitor bivalirudin was associated with increased bleeding compared with UFH in HERO-2, more recent trials have focused on its potential as a substitute for UFH plus IIb/IIIa inhibitors (and hence potential for reduced bleeding) during PCI. The ongoing HORIZONS trial will provide important data regarding bivalirudin’s role in primary PCI. However as most STEMI patients continue to receive a primary fibrinolytic strategy, a head-to-head comparison of fondaparinux and bivalirudin with dose adjusted enoxaparin in a clearly-defined, fibrinolytic-treated population is eagerly awaited.

References
Antman EM, Morrow DA, McCabe CH, et al. 2006. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England Journal of Medicine, 354:1477–88.
Antman EM, Anbe DT, Armstrong PW, et al. 2004. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation, 110:588–636.
Antman EM, Louwenerburg HW, Baars HF, et al. 2002. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation, 105:1642–9.
Antman EM. 2001. The search for replacements for unfractionated heparin. Circulation, 103:2310–14.
Antman EM, Giugliano RP, Gibson CM, et al. 1999. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation, 99:2720–32.
Antman EM and the TIMI 9B Investigators. 1996. Hirudin in Acute Myocardial Infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation, 94:911–21.
Armstrong PW. 1997. Heparin in acute coronary disease – requiem for a heavyweight? The New England Journal of Medicine, 337:492–4.
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. 2001. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 358:605–13.
Baird SH, Menown IB, McBride SJ, et al. 2002. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. European Heart Journal, 23:627–32.
Boersma E, Maas AC, Deckers JW, et al. 1996. Early thrombolysis treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet, 348:771–5.
Braunwald E, Antman EM, Beasley JW, et al. 2002. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation, 106:1893–900.
Chen ZM, Jiang LX, Chen YP, et al. 2005. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 366:1607–21.
Collins R, MacMahon S, Flather M, et al. 1996. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. British Medical Journal, 313:652–9.
Corti R, Fuster V, Badimon JJ. 2003. Pathogenetic concepts of acute coronary syndromes. Journal of the American College of Cardiology, 41(14 Suppl S):75–85.
Coussemere PK, Bassand JP, Convens C, et al. 2001. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. European Heart Journal, 22:1716–24.
Davies MJ. 2000. The pathophysiology of acute coronary syndromes. Heart, 83:361–6.
DeWood MA, Spores J, Notske R, et al. 1980. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. The New England Journal of Medicine, 303:897–902.
Efird LE, Kockler DR. 2006. Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia. The Annals of Pharmacotherapy, 40:1383–7.
Eikelboom JW, Quinlan DJ, Mehta SR, et al. 2005. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation, 112:3855–67.
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. 1994. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 343:311–2.
Gibson CM, Murphy SA, Montalescot G, et al. 2007. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Journal of the American College of Cardiology, 49:2238–46.
Giugliano RP, McCabe CH, Antman EM, et al. 2001. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. American Heart Journal, 141:742–50.
Goldberg RJ, Spencer FA, Yarzebski J, et al. 2004. A 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study). The American Journal of Cardiology, 94:1373–8.
Granger CB, Becker R, Tracy RP, et al. 1998. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Journal of the American College of Cardiology, 31:497–505.
Granger CB, Hirsch J, Califf RM, et al. 1996. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial. Circulation, 93:870–8.
Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). 1986. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet, 1:397–402.
Gurm HS, Lincoff AM, Lee D, et al. 2004. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO-1 trial. Journal of the American College of Cardiology, 43:542–8.
Hirsh J, Fuster V. 1994. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation, 89:1449–68.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 1988. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 2:349–60.
Keeley EC, Boura JA, Grines CL. 2003. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 361:13–20.
Kong DF, Topol EJ, Bittl JA, et al. 1999. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation, 100:2049–53.
New anticoagulant strategies in STEMI

Mahaffey KW, Granger CB, Collins R, et al. 1996. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. *The American Journal of Cardiology*, 77:551–6.

Metz BK, White HD, Granger CB, et al. 1998. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. *Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. The American Journal of Cardiology*, 31:1493–8.

Moreno PR, Falk E, Palacios IF, et al. 1994. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. *Circulation*, 90:775–8.

Neuhaus KL, Molhoek GP, Zeymer U, et al. 1999. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. *Journal of the American College of Cardiology*, 34:966–73.

Ross AM, Molhoek P, Lundergan C, et al. 2001. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). *Circulation*, 104:648–52.

Sabatine MS, Cannon CP, Gibson CM, et al. 2005. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *The New England Journal of Medicine*, 352:1179–89.

Shah PK. 2003. Mechanisms of plaque vulnerability and rupture. *Journal of the American College of Cardiology*, 41(4 Suppl S):15S–22S.

Simoons M, Krzeminska-Pakula M, Alonso A, et al. 2002. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. *European Heart Journal*, 23:1282–90.

Steg PG, Bonnefoy E, Chabaud S, et al. 2003. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. *Circulation*, 108:2851–6.

Stone GW, McLaurin BT, Cox DA, et al. 2006. Bivalirudin for patients with acute coronary syndromes. *The New England Journal of Medicine*, 355:2203–16.

The GUSTO Angiographic Investigators. 1993. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. *The New England Journal of Medicine*, 329:1615–22.

Walenga JM, Jeske WP, Bara L, et al. 1997. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. *Thrombosis Research*, 86:1–36.

Warkentin TE, Levine MN, Hirsh J, et al. 1995. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *The New England Journal of Medicine*, 332:1330–5.

White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. 2001. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. *Lancet*, 358:1855–63.

White HD, Aylward PE, Frey MJ, et al. 1997. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. *Circulation*, 96:2155–61.

Yusuf S, Mehta SR, Chrolavicius S, et al. 2006. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. *The Journal of the American Medical Association*, 295:1519–30.

Yusuf S, Mehta SR, Xie C, et al. 2005. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. *The Journal of the American Medical Association*, 293:427–35.
